healthcare
Portfolio: Advent International and CARE Hospitals
A majority stake in CARE Hospitals has allowed Advent International into India’s fast-growing healthcare sector. Rather than blindly pursuing expansion, the PE firm is building a business tailored to local demand
China New Oriental CEO launches $32m angel fund
Michael Yu, co-founder and CEO of New Oriental Education & Technology Group, has partnered with Xitai Shen, a former CEO of Huatai United Securities, to launch a RMB200 million ($32 million) angel investment fund.
AIA, Nest set up accelerator for Hong Kong start-ups
AIA Group has teamed up with early-stage investor Nest to form a Hong Kong-based accelerator that will support start-ups with technologies relevant to the insurance and healthcare industries.
JD Capital buys traditional Chinese medicine business
JD Capital has bought a 60% stake in Baoding Zhong Yao, a traditional Chinese medicine (TCM) manufacturer.
BVCF leads Series A for Shanghai immunotherapy firm
China-focused healthcare investor BVCF has led an undisclosed Series A round of funding for CARsgen, an immunotherapy firm that focuses on treating cancer.
China's Ally Bridge ventures into German healthcare
Ally Bridge Group, a healthcare-focused PE firm based in Hong Kong and the US, has made its first investment in Europe, participating in a EUR6.6 million ($8 million) round of funding for Pieris, a Munich-based clinical-stage biotechnology firm.
Lighthouse leads $5m Series C round for hearing aid maker
Shanghai-based Lighthouse Capital has led a $5 million Series C round of funding for affordable hearing aid maker iHear Medical.
Fosun, Nanjing Sinolife to acquire New Zealand nutrients maker
Fosun Capital and Nanjing Sinolife United have formed a joint venture to acquire Good Health Products, a New Zealand-based nutritional supplements maker and distributor, for NZ$23.37 million ($18 million).
Fidelity commits $10m to China medical device maker Eyebright
Fidelity Growth Partners Asia and Fidelity Biosciences have committed RMB62.5 million ($10 million) to Eyebright Medical Technology, a Chinese ophthalmic medical devices manufacturer.
J-Star in hospice care double deal
Not for the first time, J-Star planted the seeds of its latest investment while in pursuit of another deal.
Taiwan’s Fubon commits $30m to US-based Athyrium credit fund
Fubon Life, the second-largest insurer in Taiwan, has committed $30 million to Athyrium Capital Management’s healthcare-focused credit fund.
Baring Asia buys Japanese drug maker from Tokio Marine
Baring Private Equity Asia has agreed to buy Japan-based Bushu Pharmaceuticals from Tokio Marine Capital at an enterprise valuation of JPY77.3 billion ($670 million).
Hillhouse, CITIC PE commit $75m to Chinese cancer drug developer
Hillhouse Capital and CITIC Private Equity have participated in a RMB450 million ($75 million) round of funding for BeiGene, a Chinese company that develops drugs to combat cancer.
Japan's J-Star buys two healthcare providers
Japanese mid-market buyout firm J-Star has acquired two new care providers - Nagoya-headquartered Nurse Call and Kanagawa-based Kairos & Company - within weeks of its 5x exit from similar business HCM Corporation.
SIG, SoftBank back China wearables maker Codoon
SoftBank China Venture Capital (SBCVC) and SIG Asia have invested $30 million in a Series B round of funding for Codoon, a Chinese wearable electronic devices manufacturer.
Chinese pharma company invests $22m in TPG biotech fund
Chinese drug maker Shenzhen Hepalink Pharmaceutical, previously a highly successful PE investment for Goldman Sachs, has committed $22 million to TPG Capital’s latest biotech fund.
J-Star secures 5x exit from healthcare firm HCM - update
Japanese mid-market buyout firm J-Star has exited Tokyo-based healthcare service provider HCM Corporation to Alshok Group at an enterprise value of JPY8.88 billion ($78.7 million), generating a 5x cash multiple and a 60% IRR.
Hony eyes buyout opportunities in healthcare, restaurants
China-focused GP Hony Capital is seeing more buyout opportunities involving healthcare and restaurant chains and it has created two sector-focused operational teams to consolidate these industries.
Warburg Pincus invests $90m in India's Laurus Labs, Fidelity part exits
Warburg Pincus has paid INR5.5 billion ($89.6 million) for a minority stake in Indian drug maker Laurus Labs, triggering a partial exit for Fidelity Growth Partners India.
BVCF-backed Jaguar Animal Health targets $54m US IPO
Jaguar Animal Health, a veterinary drugs developer backed by China-focused healthcare investor BVCF, is looking to raise as much as $54 million through a NASDAQ IPO.
PE-backed Luye Pharma to take full ownership of Beijing Jialin
Luye Pharma Group, a PE-backed Chinese drug maker, has taken full ownership of its industry peer Beijing Jialin Pharmaceutical, acquiring a 42.02% interest from existing PE shareholders.
Fidelity Asia invests $15m in Chinese orthopedic hospital operator
Fidelity Growth Partners Asia has invested RMB90 million ($15 million) in Zhejiang Banger Medical Management, a Chinese orthopedic hospital operator.
Fidelity, Somerset back India's Cygnus Medicare
Fidelity Growth Partners and existing backer Somerset Indus CapitalFund have invested INR600 million ($9.7 million) in Cygnus Medicare, an Indian operator of specialty hospitals in Delhi and Haryana.
Qiming-backed life science firm BBI files for Hong Kong IPO
BBI Life Sciences Corporation, a Chinese genetic engineering specialist backed by Qiming Venture Partners, has filed for an IPO in Hong Kong. The company has yet to disclose the size and pricing of the offering.